Stanley M. Kanai

Stanley M. Kanai

Auto-generated profile, based on publicly available information

Stanley M. Kanai

School of Dental Medicine, University of Colorado Anschutz Medical Campus 1 Department of Craniofacial Biology Aurora, CO 80108

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
MOMichael D. Onken
Michael D. Onken
CMCarol M. Makepeace
Carol M. Makepeace
KKKevin M. Kaltenbronn
Kevin M. Kaltenbronn
SKStanley M. Kanai
Stanley M. Kanai
TTTyson D. Todd
Tyson D. Todd
KBKendall Jay Blumer
Kendall Jay Blumer
Constitutively active G protein α subunits cause cancer, cholera, Sturge-Weber syndrome, and other disorders. Therapeutic intervention by targeted inhibition of constitutively active Gα subunits in these disorders has yet to be achieved. We found that constitutively active Gαq in uveal melanoma (UM) cells was inhibited by the cyclic depsipeptide FR900359 (FR). FR allosterically inhibited guanosine diphosphate–for–guanosine triphosphate (GDP/GTP) exchange to trap constitutively active Gαq in inactive, GDP-bound Gαβγ heterotrimers. Allosteric inhibition of other Gα subunits was achieved by the introduction of an FR-binding site. In UM cells driven by constitutively active Gαq, FR inhibited second messenger signaling, arrested cell proliferation, reinstated melanocytic differentiation, and stimulated apoptosis. In contrast, FR had no effect on BRAF-driven UM cells. FR promoted UM cell differentiation by reactivating polycomb repressive complex 2 (PRC2)–mediated gene silencing, a heretofore unrecognized effector system of constitutively active Gαq in UM. Constitutively active Gαq and PRC2 therefore provide therapeutic targets for UM. The development of FR analogs specific for other Gα subunit subtypes may provide novel therapeutic approaches for diseases driven by constitutively active Gα subunits or multiple G protein–coupled receptors (GPCRs) where targeting a single receptor is ineffective.

11 December 2023 in Development
Verified
Journal Article
Closed access
PDF file
SKStanley M. Kanai
Stanley M. Kanai
DCDavid E. Clouthier
David E. Clouthier
Since the discovery of endothelin 1 (EDN1) in 1988, the role of endothelin ligands and their receptors in the regulation of blood pressure in normal and disease states has been extensively studied. However, endothelin signaling also plays crucial roles in the development of neural crest cell-derived tissues. Mechanisms of endothelin action during neural crest cell maturation have been deciphered using a variety of in vivo and in vitro approaches, with these studies elucidating the basis of human syndromes involving developmental differences resulting from altered endothelin signaling. In this Review, we describe the endothelin pathway and its functions during the development of neural crest-derived tissues. We also summarize how dysregulated endothelin signaling causes developmental differences and how this knowledge may lead to potential treatments for individuals with gene variants in the endothelin pathway.

1 September 2021 in Development
Verified
Journal Article
Open access
PDF file
MAMakoto Abe
Makoto Abe
Timothy CoxTimothy Cox
Timothy Cox
AFAnthony B. Firulli
Anthony B. Firulli
SKStanley M. Kanai
Stanley M. Kanai
JDJacob Dahlka
Jacob Dahlka
DCDavid E. Clouthier
David E. Clouthier
Neural crest cells (NCCs) within the mandibular and maxillary prominences of the first pharyngeal arch are initially competent to respond to signals from either region. However, mechanisms that are only partially understood establish developmental tissue boundaries to ensure spatially correct patterning. In the ‘hinge and caps’ model of facial development, signals from both ventral prominences (the caps) pattern the adjacent tissues whereas the intervening region, referred to as the maxillomandibular junction (the hinge), maintains separation of the mandibular and maxillary domains. One cap signal is GATA3, a member of the GATA family of zinc-finger transcription factors with a distinct expression pattern in the ventral-most part of the mandibular and maxillary portions of the first arch. Here, we show that disruption of Gata3 in mouse embryos leads to craniofacial microsomia and syngnathia (bony fusion of the upper and lower jaws) that results from changes in BMP4 and FGF8 gene regulatory networks within NCCs near the maxillomandibular junction. GATA3 is thus a crucial component in establishing the network of factors that functionally separate the upper and lower jaws during development.

29 April 2022 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
SKStanley M. Kanai
Stanley M. Kanai
CHCaleb Heffner
Caleb Heffner
Timothy CoxTimothy Cox
Timothy Cox
MCMichael Lorraine Cunningham
Michael Lorraine Cunningham
FPFrancisco A. Perez
Francisco A. Perez
DCDavid E. Clouthier
David E. Clouthier
Auriculocondylar syndrome 2 (ARCND2) is a rare autosomal dominant craniofacial malformation syndrome linked to multiple genetic variants in the coding sequence of phospholipase C β4 (PLCB4). PLCB4 is a direct signaling effector of the endothelin receptor type A (EDNRA)-Gq/11 pathway, which establishes the identity of neural crest cells (NCCs) that form lower jaw and middle ear structures. However, the functional consequences of PLCB4 variants on EDNRA signaling is not known. Here, we show, using multiple signaling reporter assays, that known PLCB4 variants resulting from missense mutations exert a dominant-negative interference over EDNRA signaling. In addition, using CRISPR/Cas9, we find that F0 mouse embryos modeling one PLCB4 variant have facial defects recapitulating those observed in hypomorphic Ednra mouse models, including a bone that we identify as an atavistic change in the posterior palate/oral cavity. Remarkably, we have identified a similar osseous phenotype in a child with ARCND2. Our results identify the disease mechanism of ARCND2, demonstrate that the PLCB4 variants cause craniofacial differences and illustrate how minor changes in signaling within NCCs may have driven evolutionary changes in jaw structure and function. This article has an associated First Person interview with the first author of the paper.

5 March 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
APAmanda Barone Pritchard
Amanda Barone Pritchard
SKStanley M. Kanai
Stanley M. Kanai
BKBryan Krock
Bryan Krock
ESErica Schindewolf
Erica Schindewolf
JOJennifer Oliver‐Krasinski
Jennifer Oliver‐Krasinski
DCDavid E. Clouthier
David E. Clouthier

1 November 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SKStanley M. Kanai
Stanley M. Kanai
AEAlethia J. Edwards
Alethia J. Edwards
JRJoel G. Rurik
Joel G. Rurik
POPatrick Osei-Owusu
Patrick Osei-Owusu
KBKendall Jay Blumer
Kendall Jay Blumer
Regulator of G protein signaling 2 (RGS2) controls signaling by receptors coupled to the Gq/11 class heterotrimeric G proteins. RGS2 deficiency causes several phenotypes in mice and occurs in several diseases, including hypertension in which a proteolytically unstable RGS2 mutant has been reported. However, the mechanisms and functions of RGS2 proteolysis remain poorly understood. Here we addressed these questions by identifying degradation signals in RGS2, and studying dynamic regulation of Gq/11-evoked Ca2+ signaling and vascular contraction. We identified a novel bipartite degradation signal in the N-terminal domain of RGS2. Mutations disrupting this signal blunted proteolytic degradation downstream of E3 ubiquitin ligase binding to RGS2. Analysis of RGS2 mutants proteolyzed at various rates and the effects of proteasome inhibition indicated that proteolytic degradation controls agonist efficacy by setting RGS2 protein expression levels, and affecting the rate at which cells regain agonist responsiveness as synthesis of RGS2 stops. Analyzing contraction of mesenteric resistance arteries supported the biological relevance of this mechanism. Because RGS2 mRNA expression often is strikingly and transiently up-regulated and then down-regulated upon cell stimulation, our findings indicate that proteolytic degradation tightly couples RGS2 transcription, protein levels, and function. Together these mechanisms provide tight temporal control of Gq/11-coupled receptor signaling in the cardiovascular, immune, and nervous systems.